HomeCompareALIM vs ADC

ALIM vs ADC: Dividend Comparison 2026

ALIM yields 36.10% · ADC yields 4.11%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ALIM wins by $10.1K in total portfolio value
10 years
ALIM
ALIM
● Live price
36.10%
Share price
$5.54
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$187.1K
Annual income
$29,005.40
Full ALIM calculator →
ADC
Agree Realty Corporation
● Live price
4.11%
Share price
$75.38
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$176.9K
Annual income
$79,647.25
Full ADC calculator →

Portfolio growth — ALIM vs ADC

📍 ALIM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALIMADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALIM + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALIM pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALIM
Annual income on $10K today (after 15% tax)
$3,068.59/yr
After 10yr DRIP, annual income (after tax)
$24,654.59/yr
ADC
Annual income on $10K today (after 15% tax)
$349.45/yr
After 10yr DRIP, annual income (after tax)
$67,700.16/yr
At 15% tax rate, ADC beats the other by $43,045.57/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALIM + ADC for your $10,000?

ALIM: 50%ADC: 50%
100% ADC50/50100% ALIM
Portfolio after 10yr
$182.0K
Annual income
$54,326.32/yr
Blended yield
29.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

ALIM
Analyst Ratings
9
Buy
4
Hold
Consensus: Buy
Price Target
$5.75
+3.8% upside vs current
Range: $5.50 — $6.00
Altman Z
-1.4
Piotroski
1/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+7.5% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALIM buys
0
ADC buys
0
No recent congressional trades found for ALIM or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALIMADC
Forward yield36.10%4.11%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$187.1K$176.9K
Annual income after 10y$29,005.40$79,647.25
Total dividends collected$136.3K$154.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$5.75$81.06

Year-by-year: ALIM vs ADC ($10,000, DRIP)

YearALIM PortfolioALIM Income/yrADC PortfolioADC Income/yrGap
1← crossover$14,310$3,610.11$10,987$577.21+$3.3KALIM
2$20,140$4,828.13$12,293$855.34+$7.8KALIM
3$27,900$6,350.55$14,088$1,290.70+$13.8KALIM
4$38,075$8,222.00$16,660$1,994.91+$21.4KALIM
5$51,227$10,486.45$20,525$3,181.85+$30.7KALIM
6$67,999$13,185.62$26,654$5,286.90+$41.3KALIM
7$89,116$16,357.51$37,006$9,259.47+$52.1KALIM
8$115,389$20,035.00$55,862$17,338.74+$59.5KALIM
9$147,711$24,244.58$93,452$35,300.32+$54.3KALIM
10$187,056$29,005.40$176,931$79,647.25+$10.1KALIM

ALIM vs ADC: Complete Analysis 2026

ALIMStock

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Full ALIM Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this ALIM vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALIM vs SCHDALIM vs JEPIALIM vs OALIM vs KOALIM vs MAINALIM vs NNNALIM vs EPRTALIM vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.